News: The Latest

Bicara Therapeutics to Present at Upcoming November Investor Conferences

November 8, 2021

CAMBRIDGE, Mass., November 8, 2021 – Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics designed to elicit a potent and durable immune response in the tumor microenvironment, today announced that company leadership will participate in two upcoming virtual investor conferences in November:

Stifel 2021 Virtual Healthcare Conference
Format: Live presentation

Date: Monday, November 15, 2021
Time: 10:40 – 11:10 a.m. ET

Piper Sandler 33rd Annual Virtual Healthcare Conference
Format: On-demand presentation

Date: Monday, November 22, 2021
Time: 10:00 a.m. ET

About Bicara Therapeutics:

Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of immunotherapy. The company’s bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy. Bicara’s lead asset, BCA101, a first-in-class EGFR / TGF-β-trap bifunctional antibody, is currently enrolling patients in a Phase 1/2 study. Bicara’s experienced team brings deep expertise across immunology, oncology, clinical development, business development and operational strategy.


Sarah McCabe
Stern Investor Relations, Inc.
[email protected]

Chris Railey
Ten Bridge Communications
[email protected]